Naltrexone

Generic Name
Naltrexone
Brand Names
Contrave, Embeda, Vivitrol
Drug Type
Small Molecule
Chemical Formula
C20H23NO4
CAS Number
16590-41-3
Unique Ingredient Identifier
5S6W795CQM
Background

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Indication

Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.

Associated Conditions
Alcohol Dependency, Cholestatic pruritus, Obesity, Opioid Dependence, Severe Pain
Associated Therapies
-
Clinical Trials
Related News

Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions

First Posted Date
2014-05-14
Last Posted Date
2014-12-12
Lead Sponsor
INSYS Therapeutics Inc
Target Recruit Count
12
Registration Number
NCT02138396
Locations
🇺🇸

Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

First Posted Date
2014-05-13
Last Posted Date
2021-11-16
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
3
Registration Number
NCT02137252
Locations
🇺🇸

Massachusetts General Hosptial, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Naltrexone for Individuals of East Asian Descent

Phase 2
Completed
Conditions
Alcohol Use Disorder
Interventions
Drug: Naltrexone
Drug: Placebo
First Posted Date
2014-01-01
Last Posted Date
2019-07-17
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
87
Registration Number
NCT02026011
Locations
🇺🇸

UCLA Addictions Laboratory, Los Angeles, California, United States

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

First Posted Date
2013-11-25
Last Posted Date
2018-06-18
Lead Sponsor
University of Michigan
Target Recruit Count
23
Registration Number
NCT01993108
Locations
🇺🇸

Rachel Upjohn Building, East Medical Campus, Ann Arbor, Michigan, United States

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

First Posted Date
2013-09-25
Last Posted Date
2024-10-16
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
47
Registration Number
NCT01950520
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Nalrexone Facilitated Discontinuation of Buprenorphine

Phase 1
Completed
Conditions
Stable Opioid Dependence
Interventions
Drug: Naltrexone
First Posted Date
2013-07-10
Last Posted Date
2018-06-15
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
6
Registration Number
NCT01895036
Locations
🇺🇸

NYSPI, New York, New York, United States

Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence

First Posted Date
2013-06-11
Last Posted Date
2017-02-24
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
12
Registration Number
NCT01874951
Locations
🇺🇸

Massachusetts General Hospital; Depression Research and Clinical Program, Boston, Massachusetts, United States

An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.

Phase 4
Completed
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Drug: Naltrexone
First Posted Date
2013-06-10
Last Posted Date
2017-01-13
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
3
Registration Number
NCT01873729
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Naltrexone for Antipsychotic-Induced Weight Gain

First Posted Date
2013-05-31
Last Posted Date
2021-10-01
Lead Sponsor
Yale University
Target Recruit Count
144
Registration Number
NCT01866098
Locations
🇺🇸

Connecticut Mental Health Center, New Haven, Connecticut, United States

Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol Dependence

Phase 3
Completed
Conditions
Alcohol Dependence
Interventions
Drug: Naltrexone
First Posted Date
2013-05-17
Last Posted Date
2019-03-05
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
54
Registration Number
NCT01856712
Locations
🇺🇸

University of Wisconsin - Department of Family Medicine, Madison, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy